Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis.

Lundquist LM, Cole SW, Augustine JM.

Open Access Rheumatol. 2012 Feb 2;4:9-19. Review.

3.
4.

Arthritis in pregnancy: the role and safety of biological agents.

Youssef P, Kennedy D.

Obstet Med. 2009 Dec;2(4):134-7. doi: 10.1258/om.2009.090023. Review.

5.

Functions of interleukin-34 and its emerging association with rheumatoid arthritis.

Zhou RP, Wu XS, Xie YY, Dai BB, Hu W, Ge JF, Chen FH.

Immunology. 2016 Dec;149(4):362-373. doi: 10.1111/imm.12660. Review.

PMID:
27550090
6.

Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus.

Dahal LN, Basu N, Youssef H, Khanolkar RC, Barker RN, Erwig LP, Ward FJ.

Arthritis Res Ther. 2016 Aug 4;18:180. doi: 10.1186/s13075-016-1075-1.

7.

Interleukin-6 (IL-6) Receptor Antagonist Protects Against Rheumatoid Arthritis.

Li S, Wu Z, Li L, Liu X.

Med Sci Monit. 2016 Jun 20;22:2113-8.

8.
9.

Analysis of Mitogen-Activated Protein Kinases in Bone and Cartilage of Patients with Rheumatoid Arthritis Treated with Abatacept.

Kanbe K, Oh K, Chiba J, Inoue Y, Taguchi M, Yabuki A.

Clin Med Insights Arthritis Musculoskelet Disord. 2016 Apr 10;9:51-6. doi: 10.4137/CMAMD.S34424.

10.

Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis.

Vierboom MP, Breedveld E, Kap YS, Mary C, Poirier N, 't Hart BA, Vanhove B.

Clin Exp Immunol. 2016 Mar;183(3):405-18. doi: 10.1111/cei.12739.

PMID:
26540618
11.

Short-Term Efficacy Reliably Predicts Long-Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-Based Meta-Analysis.

Wang Y, Zhu R, Xiao J, Davis JC Jr, Mandema JW, Jin JY, Tang MT.

J Clin Pharmacol. 2016 Jul;56(7):835-44. doi: 10.1002/jcph.668.

12.

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries.

Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, Hetland ML, Pavelka K, Gottenberg JE, Canhão H, Mariette X, Turesson C.

RMD Open. 2015 Apr 30;1(1):e000040. doi: 10.1136/rmdopen-2014-000040.

13.

Novel Immune Check-Point Regulators in Tolerance Maintenance.

Guo Y, Wang AY.

Front Immunol. 2015 Aug 18;6:421. doi: 10.3389/fimmu.2015.00421. Review. Erratum in: Front Immunol. 2016;7:38.

14.

Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?

Ville S, Poirier N, Blancho G, Vanhove B.

Front Immunol. 2015 Aug 10;6:411. doi: 10.3389/fimmu.2015.00411. Review.

15.

Abatacept decreases disease activity in a absence of CD4(+) T cells in a collagen-induced arthritis model.

Jansen DT, el Bannoudi H, Arens R, Habets KL, Hameetman M, Huizinga TW, Stoop JN, Toes RE.

Arthritis Res Ther. 2015 Aug 20;17:220. doi: 10.1186/s13075-015-0731-1.

16.

Quantitative and qualitative characterization of expanded CD4+ T cell clones in rheumatoid arthritis patients.

Ishigaki K, Shoda H, Kochi Y, Yasui T, Kadono Y, Tanaka S, Fujio K, Yamamoto K.

Sci Rep. 2015 Aug 6;5:12937. doi: 10.1038/srep12937.

17.

Mathematical model reveals how regulating the three phases of T-cell response could counteract immune evasion.

Lorenzi T, Chisholm RH, Melensi M, Lorz A, Delitala M.

Immunology. 2015 Oct;146(2):271-80. doi: 10.1111/imm.12500.

18.

The Aryl Hydrocarbon Receptor: A Key Bridging Molecule of External and Internal Chemical Signals.

Tian J, Feng Y, Fu H, Xie HQ, Jiang JX, Zhao B.

Environ Sci Technol. 2015 Aug 18;49(16):9518-31. doi: 10.1021/acs.est.5b00385. Review.

19.

Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation.

Wang Q, Liu D, Song P, Zou MH.

Front Biosci (Landmark Ed). 2015 Jun 1;20:1116-43. Review.

20.

Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses.

Morris G, Berk M, Walder K, Maes M.

BMC Med. 2015 Feb 6;13:28. doi: 10.1186/s12916-014-0259-2. Review.

Items per page

Supplemental Content

Support Center